Lung adenocarcinoma, a subtype of non-small cell lung cancer, has been on the rise in recent years. This alarming trend underscores the need for deeper understanding and innovative approaches to treatment. The study by Cheng et al. underscores the importance of both metabolic reprogramming and immune response in the tumor microenvironment. By unraveling the mechanisms governing CD155’s involvement in glycolytic reprogramming, researchers illuminate a possible confluence between cancer metabolism and immune modulation.

Central to their findings is the CD155 receptor, which has long been associated with immune evasion in various cancers. The study highlights that CD155 expression is not merely a passive marker but actively engages in changing metabolic pathways within tumor cells. The authors propose that CD155 orchestrates a shift towards aerobic glycolysis—a phenomenon often referred to as the Warburg effect. This shift is not just an energy-generating response; it also equips the tumor to create a favorable microenvironment for immune modulation, especially towards a M2 macrophage polarization.

Additionally, the involvement of the YAP/TEAD1 signaling pathway offers profound implications for future therapeutic strategies. YAP, a key player in the Hippo pathway, is known for its role in promoting cell growth and survival. The study boldly posits that YAP’s activation in lung adenocarcinoma cells leads to enhanced GLUT1 expression, a glucose transporter essential for the high metabolic demands of rapidly proliferating tumor cells. Strikingly, the excess glucose uptake via GLUT1 not only supports the tumor’s anabolic processes but also contributes to the immunosuppressive lacquer laid down by polarized M2 macrophages.

A noteworthy aspect of this study is its methodological approach, which elegantly combines molecular biology with advanced imaging techniques. The application of (^18)F-FDG PET/CT provides a visual representation of both metabolic activity and the tumor’s interactions with its immunological milieu. Such advanced imaging tools are revolutionizing cancer diagnostics and treatment response evaluation, placing them at the forefront of precision medicine. The utilization of these technologies illustrates a paradigm shift in understanding how tumor metabolism can inform therapeutic decisions.

While the research unveils critical connections between CD155, glycolysis, and immune polarization, it also emphasizes the need to explore the therapeutic potential of targeting these pathways. The inhibition of CD155, the YAP/TEAD1 axis, or GLUT1 could yield exciting outcomes in restoring anti-tumor immunity and halting the progression of lung adenocarcinoma. In essence, these findings serve as a clarion call for the scientific community to pivot towards integrative therapeutic strategies that tackle both metabolic and immune components of cancer.

The implications of this study extend beyond hypoxic tumors. Given that many malignancies exploit similar metabolic rewiring and immune modulation, the insights gained could have far-reaching relevance. Although the focus is primarily on lung adenocarcinoma, lessons learned here may parallel investigations into other cancer types, widening the spectrum of possible therapeutic interventions.

The research also raises critical questions regarding the interplay between metabolism and immune function in the broader context of the tumor microenvironment. As we delve deeper into these relationships, it becomes imperative to decipher the role played by various immune cell types and their mediators within the metabolic landscape of cancer. Investigating this complex web could illuminate new pathways for intervention.

In synthesis, Cheng et al.’s illuminating research not only contributes significant knowledge regarding the metabolic adaptations in lung adenocarcinoma but also emphasizes the crucial role of immune modulation via tumor metabolic changes. This integrative approach to understanding cancer highlights how therapy can be tailored to disrupt these pathways, ultimately leading to better patient outcomes in this challenging domain of oncology.

As we stand on the precipice of new findings, collaborative efforts among researchers, clinicians, and technological innovators are essential. The interplay between metabolism and immunity in cancer biology is a frontier that holds the promise of transformative health care strategies—strategies that will require precision medicine modalities such as genomic profiling and advanced imaging to fully realize their potential.

In conclusion, as the body of literature continues to grow surrounding the metabolic-immune axis in cancer, it becomes increasingly evident that the future of oncological therapy hinges on unraveling these intricate relationships. The work by Cheng et al. marks a significant step in this direction, paving the way for subsequent research aimed at manipulating these pathways to combat lung adenocarcinoma and potentially other malignancies.

Empowering oncologists with this knowledge will serve not only to innovate treatment protocols but also to enhance the conversation around the pivotal role of metabolism in cancer drive as both a direct threat to patients’ health and a potential therapeutic target.

Subject of Research: The role of CD155 in metabolic reprogramming and immune modulation in lung adenocarcinoma.

Article Title: CD155 reprograms glycolysis via the YAP/TEAD1-GLUT1 axis to promote lung adenocarcinoma progression and M2 macrophage polarization: a metabolic-immune target visualized by (^18)F-FDG PET/CT.

Article References: Cheng, Z., Wang, S., Xu, S. et al. CD155 reprograms glycolysis via the YAP/TEAD1-GLUT1 axis to promote lung adenocarcinoma progression and M2 macrophage polarization: a metabolic-immune target visualized by (^18)F-FDG PET/CT. J Transl Med (2025). https://doi.org/10.1186/s12967-025-07551-7

Image Credits: AI Generated

DOI:

Keywords: lung adenocarcinoma, CD155, glycolysis, YAP/TEAD1, GLUT1, immune modulation, PET/CT imaging, cancer metabolism.

Gastric cancer remains the fifth most frequently diagnosed malignancy worldwide and ranks fourth in its contribution to cancer-related deaths, underscoring the dire need for innovative interventions. Immunotherapy has heralded new hope in various cancers by harnessing the immune system to recognize and destroy malignant cells. However, the heterogeneous nature of the TME in gastric cancer poses significant challenges, often dampening immune responses and limiting therapeutic outcomes. Understanding the molecular underpinnings that shape this environment is crucial, and CD2AP has now been thrust into the spotlight as a key regulator.

CD2AP is traditionally known for its role in cytoskeletal organization and cell signaling, but its involvement in cancer immunology remained ambiguous until now. Utilizing comprehensive RNA sequencing data from The Cancer Genome Atlas (TCGA), the research team conducted a pan-cancer analysis, meticulously profiling CD2AP expression across multiple malignancies. Remarkably, CD2AP expression was found upregulated within the stromal compartments of various tumors, hinting at a conserved role in TME architecture and immune modulation.

Focusing specifically on stomach adenocarcinoma, the researchers employed robust bioinformatics pipelines to dissect the association between CD2AP levels and critical immunological features. These included the elaborate cancer immunity cycle stages, expression patterns of immune checkpoint molecules, immunomodulatory factors, and the prevalence of tumor-infiltrating immune cells (TIICs). This multi-dimensional analysis illuminated how CD2AP correlates with a ‘stromal reduced’ TME—a microenvironment characterized by diminished stromal content but potentially heightened immune cell activity.

This ‘stromal reduced’ milieu correlated positively with enhanced immunotherapy responsiveness, positioning CD2AP not merely as a bystander but as an active contributor to shaping the immune contexture that favors therapeutic success. Patients exhibiting elevated CD2AP expression concurrently showed increased markers such as CD4, CD20, and CD57, each reflecting pivotal immune subsets including helper T cells, B cells, and natural killer cells respectively. This triad of high immune marker expression combined with CD2AP abundance was associated with improved prognosis and survival outcomes.

To translate these findings into clinical utility, the study ventured into prognostic modeling by constructing an immune-related risk score (IRS) that integrates CD2AP expression with other immune parameters. The IRS demonstrated robust predictive capability for patient outcomes in STAD, potentially guiding personalized medicine approaches. This score empowers oncologists to stratify patients according to their immunological and molecular tumor profiles, refining treatment strategies to maximize immunotherapeutic efficacy.

The molecular mechanisms by which CD2AP influences the stromal composition and immune cell infiltration within the TME are of particular interest. Although fully elucidating this requires further investigation, initial data suggest CD2AP modulates signaling pathways that regulate stromal cell activation and extracellular matrix deposition. By limiting excessive stromal expansion, CD2AP helps create a microenvironment that permits better immune cell penetration and function, a prerequisite for effective immune-mediated tumor eradication.

Moreover, CD2AP’s interplay with immune checkpoints and immunomodulators hints at a regulatory nexus where it could modulate the delicate balance between immune tolerance and activation within the tumor. This balance is critical for immunotherapy success, as immune evasion remains a hallmark of gastric cancer. Targeting CD2AP-related pathways could, therefore, synergize with existing checkpoint inhibitors, offering a combinatorial therapeutic strategy that enhances antitumor immunity while overcoming resistance mechanisms.

This research also spotlights the heterogeneity within gastric tumors, which often confounds treatment responses. By characterizing the tumor’s stromal and immune architecture through the lens of CD2AP expression, the study provides a refined understanding of tumor biology. It underscores the importance of considering the spatial and molecular context of tumors, which may explain why some patients respond remarkably well to immunotherapy while others do not.

Beyond its prognostic and therapeutic implications, CD2AP emerges as a promising biomarker for gastric cancer, aiding in early diagnosis, risk assessment, and monitoring treatment response. Biomarkers that reflect both tumor intrinsic features and the surrounding immune milieu are invaluable, as they offer a holistic view of disease state and progression. Incorporating CD2AP measurement into routine clinical workflows could transform patient management paradigms.

It is important to note that while the study leans heavily on bioinformatic analyses using large genomic datasets, subsequent experimental validations and clinical trials are warranted to fully establish CD2AP’s role and therapeutic potential. Investigations into its functional mechanisms at the cellular and molecular levels will unravel how modulating CD2AP expression influences TME remodeling and immune activation in vivo.

The broader implications of these findings extend beyond gastric cancer. Given CD2AP’s conserved expression patterns and its involvement in the immune microenvironment of multiple cancer types, it could represent a universal target for enhancing immunotherapy across malignancies. This opens exciting possibilities for cross-cancer therapeutic strategies leveraging CD2AP modulation.

In conclusion, the identification of CD2AP as a modulator of the stromal reduced tumor microenvironment and as a facilitator of immunotherapy response marks a significant advancement in gastric cancer research. This discovery not only enriches our molecular understanding of tumor-immune interactions but also paves the way for novel diagnostic and therapeutic innovations aimed at improving patient outcomes in this devastating disease.

As the oncology community eagerly anticipates further developments, the integration of CD2AP-related molecular insights into clinical practice holds the promise of transforming how gastric cancer is diagnosed, treated, and ultimately conquered.

Subject of Research: Gastric cancer tumor microenvironment and immunotherapy modulation via CD2AP

Article Title: CD2AP shapes a stromal reduced tumor microenvironment and contributes to immunotherapy in gastric cancer

Article References:
Li, H., Chen, H., Zhao, T. et al. CD2AP shapes a stromal reduced tumor microenvironment and contributes to immunotherapy in gastric cancer. BMC Cancer 25, 910 (2025). https://doi.org/10.1186/s12885-025-14248-z

Image Credits: Scienmag.com

DOI: https://doi.org/10.1186/s12885-025-14248-z

A team of researchers, led by Dr. Edgar Engleman, MD, PhD, at Stanford University, has uncovered that EPO, traditionally seen as a hematopoietic growth factor, functions as a critical switch within the immune landscape of cancer. The study, published in the prestigious journal Science on April 24, 2025, demonstrates that by blocking EPO signaling, formerly “cold” tumors—those that evade immune detection—can be converted into “hot” tumors, rich with activated cancer-fighting immune cells, particularly T lymphocytes. This transformation holds profound therapeutic implications, especially when combined with immune checkpoint inhibitors like anti-PD-1 antibodies, such as the commercially available Keytruda.

Cold tumors are a notorious challenge in oncology because their immune-resistant nature allows unchecked cancer growth. Dr. Engleman’s group utilized sophisticated genome editing techniques to develop multiple mouse models of liver cancer that closely mirror human disease, including its genetic mutations, histological features, and response patterns to existing therapies. Leveraging these models, they observed that tumors exhibiting resistance to anti-PD-1 therapy also showed markedly elevated levels of EPO compared to tumors infiltrated by immune cells. This correlation indicated a previously unappreciated role for EPO in fostering an immunosuppressive tumor microenvironment.

Further investigation revealed that tumor-associated hypoxia, a hallmark of many solid tumors, is a driving force behind the increased expression of EPO within cold tumors. Hypoxia stimulates cancer cells to produce signals that elevate EPO levels, which, in turn, act on macrophages within the tumor. These macrophages, once activated by EPO through its receptor, shift towards an immunosuppressive phenotype, actively repelling T cells and quelling their anti-cancer activities. This crosstalk essentially creates an immune-privileged niche, enabling tumors to grow unchecked and resist current immunotherapies.

Strikingly, when the researchers genetically disrupted the tumor cells’ ability to produce EPO, the formerly cold tumors transformed into hot, inflamed tumors, abundant with active T cells. Conversely, artificially elevating EPO levels in hot tumors induced immune suppression, enabling tumor progression. These elegant experiments solidify the causal role of tumor-derived EPO as an immunosuppressive switch, shifting the tumor-immune balance toward immune evasion.

To probe the therapeutic potential of these findings, the team evaluated the combined blockade of the EPO signaling pathway and PD-1. In murine models carrying cold liver tumors, neither anti-PD-1 therapy nor controls alone improved survival beyond eight weeks post tumor induction. However, mice engineered to have macrophages deficient in EPO receptors exhibited significantly extended survival, with 40% alive at 18 weeks after tumor initiation. Strikingly, when these macrophage-specific EPO receptor knockout mice received anti-PD-1 therapy, survival extended to the full duration of the experiment, with complete tumor regression in most cases.

These results underscore that interrupting EPO signaling effectively reactivates the immune system’s ability to recognize and destroy tumors, overcoming one of the major barriers in cancer immunotherapy. Dr. Engleman emphasized that targeting EPO or its receptor could complement existing checkpoint blockade therapies, thus widening the spectrum of cancers responsive to immunotherapy—particularly liver, pancreatic, colorectal, breast, and prostate cancers, which are typically resistant to anti-PD-1 therapy.

The clinical implications extend beyond liver cancer, as analyses of patient tumor databases revealed a consistent association between high EPO expression and poorer survival across multiple tumor types, including kidney, breast, colon, and skin cancers. This highlights EPO’s broader role as a central regulator within the tumor microenvironment’s immune modulation.

Despite the promise, Dr. Engleman cautions against indiscriminate systemic inhibition of EPO due to its essential physiological role in red blood cell production, raising concerns about anemia as a potential side effect. As an alternative, strategies are under exploration to selectively target EPO receptors expressed on tumor-associated macrophages, aiming to disrupt immunosuppression without compromising erythropoiesis. This targeted approach may offer a safer therapeutic window while enhancing immune-mediated tumor clearance.

This discovery also provides a mechanistic explanation for previous clinical observations that administration of EPO to cancer patients with anemia sometimes accelerated tumor growth—a phenomenon that had puzzled clinicians and researchers for years and led to FDA black box warnings on EPO drugs. By elucidating EPO’s immunosuppressive function within tumors, the study reconciles these clinical findings within a comprehensive biological framework.

The interdisciplinary collaboration for this research included contributions from the New York Blood Center and ImmunEdge Inc., a biotechnology company co-founded by Dr. Chiu, the study’s lead author, and Dr. Engleman. Their joint efforts exemplify how academic and industrial partnerships can accelerate the translation of basic scientific insights into therapeutic innovations.

Looking forward, Dr. Engleman and his team are advancing preclinical development of EPO pathway inhibitors and designing clinical strategies to test their efficacy in human cancers. The anticipated integration of EPO receptor blockade with immune checkpoint therapy holds promise to not only improve patient outcomes but also to expand the reach of immunotherapy to presently refractory cancers.

This pioneering research reshapes fundamental concepts in cancer immunity by unveiling an unexpected role for erythropoietin—a decades-old molecule—in modulating tumor immune escape. As the field embraces these insights, the future of cancer treatment may soon harness EPO-targeted strategies to reinvigorate anti-tumor immunity and bring new hope to patients worldwide.

Subject of Research: Animals

Article Title: Tumor-derived erythropoietin acts as an immunosuppressive switch in cancer immunity

News Publication Date: 24-Apr-2025